Skip to content

Dr. Molly Li

273
Dr. Molly Li
李兆澄
Share
qualifications
MBBS (HK) MRCP (UK) FHKCP FHKAM (medical oncology)
rank
Assistant Professor (Clinical) – Department of Clinical Oncology
orcid
0000-0002-6460-5514
email
molly@clo.cuhk.edu.hk

Specific Research / Sites of Interest

Lung Cancer

  • Clinical Trials and Therapeutic development

  • Screening in never-smokers

  • Biomarker development

Short Biography

Dr Molly Li received his medical degree (MBBS) from the University of Hong Kong in 2014 with distinction in medicine. He obtained specialist qualification in Medical Oncology in 2021 and joined the Chinese University of Hong Kong as Assistant Professor in 2022. His research focus is on lung cancer.

Dr Li’s research interest is in lung cancer screening and therapeutic development. He is currently the principal investigator or co-investigator of more than 20 lung cancer clinical trials. He is in the steering committees of a few global clinical trials, and leads a few multi-centre investigator-initiated trials (CITADEL, NCT06055465, a phase II trial investigating perioperative pembrolizumab and sacituzumab govitecan in resectable lung cancer; ATOM2, a phase II randomized trial investigating the role of consolidative radiotherapy in patients with EGFR mutated lung cancer and oligoresidual disease after targeted therapy) and an AI-guided lung cancer screening study (LC-SHIELD, NCT06295497) in Hong Kong.

Awards and Grants
Health and Medical Research Fund 2024
Silver Medal, the Hong Kong Academy of Medicine Best Original Research by Young Fellow 2023
Young Investigator Research Grant, Hong Kong College of Physicians 2022, 2024
Direct Grant, The Chinese University of Hong Kong 2022, 2023, 2024
Young Investigator Grant, International Association for the Study of Lung Cancer 2022

Invited speaker in multiple locoregional conferences e.g. ESMO Lung Cancer Advance Courses, ESMO Asia, Chinese Thoracic Oncology Research Group (CTONG) conferences, Korean Association for Lung Cancer annual conference, etc.

International academic roles
American Society of Clinical Oncology Leadership Development Programme Asia Pacific 2023 – 2024
The Lancet Respiratory Medicine (journal) – International advisory board 2023 - present
Lung cancer (journal) – Editorial Board member 6/2025 - present
Therapeutic advances in medical oncology (journal) – Editorial review board member 5/2024 – present
International Association for the Study of Lung Cancer (IASLC) podcast – Guest Host in Lung Cancer Considered in Cantonese
Reviewer: Lancet Respiratory Medicine, Journal of Thoracic Oncology (#3 highest reviewer in 2024), Cell Reports Medicine, NPJ Precision Oncology, Signal Transduction and Targeted Therapy Lung Cancer

Public services
Member of Cancer Expert Working Group on Cancer Prevention and Screening (Department of Health, Hong Kong) 8/2024 – present
Working Group on the Development of Lung Cancer Services (Hospital Authority, Hong Kong) 12/2023 – present

Most Representative Publications

1. Jing Zhao, Wanting Xu, Fei Zhou, Xiangyu Zhang, Mo Zhou, Da Miao, Lan Yu, Yongchang Zhang, Junqiang Fan, Caicun Zhou, Wen Li, Tony Mok, Xiuning Le#, Molly Li# (co-corresponding author), Yang Xia#. Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC – mechanisms and evolving treatment approaches. Nature Review Clinical Oncology (accepted)
2. Allen CC Chen, Florence ST Mok, Wesley Wong, Benjamin HW Lam, David Johnson, Matthew MP Lee, Landon L Chan, Frankie Mo, Kevin KS Mok, Olivia H Chen, Kirsty Lee, Herbert HF Loong, KC Lam, Kelvin Yan, Tony SK Mok, Molly SC Li (corresponding author). Pattern of failure, impact of local therapy, and characteristics of long-term responders with advanced EGFR mutation positive non-small cell lung cancer treated with first-line osimertinib: a retrospective study. Lung Cancer (accepted)
3. Stephanie PL Saw, Wen Zhao Zhong, Rui Fu, Molly SC Li, Yasushi Goto, Stephen B Fox, Yasushi Yatabe, Boon-Hean Ong, Calvin SH Ng, David DW Lee, Pham Cam Phuong, In Kyu Park, James CH Yang, Masahiro Tsuboi, Lye Mun Tho, Thomas John, Hsao-Hsun Hsu, Daniel SW Tan, Tony SK Mok, Thanyanan Reungwetwattana, Navneet Singh. Asian Thoracic Oncology Research Group expert consensus statement on the peri-operative management of non-small cell lung cancer. Lung Cancer. 2025 Fev:200:108076.
4. Molly SC Li (corresponding author), Stephanie PL Saw, Alfredo Addeo. The debate on anti-CTLA4 in NSCLC: insights from NIPPON. The Lancet Respiratory Medicine. August 16, 2024.
5. S. P. L. Saw, Y. F. Low, G. G. Y. Lai, L. L. Chan, W. K. Y. Wong, G. Tsui, O. H. Chen, A. O. L. Seet, W. C. Tan, A. C. Tan, J. W. K. Chan, Y. L. Teh, W. L. Tan, Q. S. Ng, M. K. Ang, R. Kanesvaran, D. W. T. Lim, D. S. W. Tan, T. S. K. Mok, M. S. C. Li. Real-world outcomes of pemetrexed-platinum chemotherapy plus osimertinib after progression on first-line osimertinib in advanced EGFR-mutated NSCLC. Lung Cancer. Volume 193, 107856, July 2024
6. K. W. C. Lee, M. S. C. Li*, W. Gai, Y. M. Lau, A. K. C. Chan, O. S. H. Chan, C. K. Lee, R. M. W. Yeung, S. Y. H. Fung, W. F. Cheung, V. W. Chan, L. Leung, K. N. P. Kam, T. S. K. Mok. EGFR Mutation Testing in Pleural and Pericardial Effusion Cell-free DNA from Lung Cancer: A Prospective Validation Study. (*co-first authorship). JAMA Oncology. 2022 Dec 29.